Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Charles D. Loftin"'
Autor:
Lauren M. Weaver, Madeline J. Stewart, Kai Ding, Charles D. Loftin, Fang Zheng, Chang-Guo Zhan
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Abdominal aortic aneurysm (AAA) is a deadly, permanent ballooning of the aortic artery. Pharmacological and genetic studies have pointed to multiple proteins, including microsomal prostaglandin E2 synthase-1 (mPGES-1), as potentially promisi
Externí odkaz:
https://doaj.org/article/719d64beb3d04e969ef849bcfb2a61e3
Autor:
Madeline J. Stewart, Lauren M. Weaver, Kai Ding, Annet Kyomuhangi, Charles D. Loftin, Fang Zheng, Chang-Guo Zhan
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract The growing opioid use and overdose crisis in the US is closely related to the abuse of pain medications. Particularly for postoperative pain (POP), ~ 310 million major surgeries are performed globally per year. Most patients undergoing surg
Externí odkaz:
https://doaj.org/article/8c5238deb2454e65a372bea92237677f
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 153, Iss , Pp 113340- (2022)
The cardiovascular field is still searching for a treatment for abdominal aortic aneurysms (AAA). This inflammatory disease often goes undiagnosed until a late stage and associated rupture has a high mortality rate. No pharmacological treatment optio
Externí odkaz:
https://doaj.org/article/f1ddb69acc0e4a548027ca9bfa97ef95
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ideal target for next generation of anti-inflammatory drugs without the side effects of currently available anti-inflammatory drugs. However, there has been no clinically promising mPGES
Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice.
Autor:
Sarbani Ghoshal, Charles D Loftin
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e44369 (2012)
Abdominal aortic aneurysms (AAAs) are a chronic inflammatory disease that increase the risk of life-threatening aortic rupture. In humans, AAAs have been characterized by increased expression of cyclooxygenase-2 and the inactivation of COX-2 prior to
Externí odkaz:
https://doaj.org/article/d2bb6174c47b49b49fa426804e162f25
Publikováno v:
Acta Crystallographica Section E, Vol 65, Iss 2, Pp o360-o360 (2009)
In the title compound, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole (SC-560), C17H12ClF3N2O, a COX-1-selective inhibitor, the dihedral angles between the heterocycle and the chlorobenzene and methoxybenzene rings are 41.66 (
Externí odkaz:
https://doaj.org/article/a0dc307a71b345c5a93fd4224cd9377a
Publikováno v:
Journal of Cardiovascular Pharmacology. 68:127-142
The development of numerous types of cardiovascular disease is associated with alteration of the vascular smooth muscle cell (SMC) phenotype. We have previously shown that abdominal aortic aneurysm progression in a mouse model of the disease is assoc
Autor:
Julie H. Oestreich, Wendell S. Akers, Suellen P. Ferraris, Steven R. Steinhubl, Charles D. Loftin
Publikováno v:
Journal of Thrombosis and Thrombolysis. 38:372-379
In platelets, thrombin receptor signaling depends upon the release of adenosine diphosphate and subsequent activation at purinergic subtype Y (P2Y) receptors. The purpose of this study is to evaluate the influence of specific P2Y12 polymorphisms on p
Autor:
James A. Clark, Laura M. DeGraff, Darshini B. Trivedi, Darryl C. Zeldin, Robert Langenbach, Page Myers, Charles D. Loftin, Jennifer Cheng
Publikováno v:
Circulation Research. 112:1219-1229
Rationale: Abdominal aortic aneurysms (AAAs) are a chronic inflammatory vascular disease for which pharmacological treatments are not available. A mouse model of AAA formation involves chronic infusion of angiotensin II (AngII), and previous studies
Publikováno v:
The FASEB Journal. 29
INTRODUCTION In a mouse model of abdominal aortic aneurysms (AAAs) induced by chronic angiotensin II (AngII) infusion, the effectiveness of cyclooxygenase-2 (COX-2) inhibition in attenuating AAA pr...